Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
Minghui’s MHB088C will soon start phase 3 in China.
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
The first global pivotal trial will be in first-line triple-negative breast cancer.